Join Growin Stock Community!

Amgen inc(AMGN.US AI Earnings Summary)

US StockHealthcare
No presentation for AMGN

AMGN AI Earnings Summary (In-Depth)

Last updated: 2026-11-03 (US time)

2026 Q3

Core Highlights

  • Against Prior Guidance: Non-GAAP operating margin reached 47%, approximately 1 percentage point above the upper end of the guidance. The median 2026 full-year total revenue guidance provided last quarter was $38.8 billion; this quarter, management raised the full-year total revenue expectation to $38.9 billion–$39.7 billion (median $39.3 billion), indicating higher operational growth momentum than previously expected.
  • In One Sentence: AMGEN INC relied on the strong push of its six major growth engines to drive quarterly total revenue past the $10 billion mark and raised its full-year revenue outlook.

Quarterly Highlights

Six major growth engines accelerated simultaneously, delivering strong across-the-board financial performance this quarter.

  1. Six core growth engines grew 27% YoY collectively, accounting for over 70% of revenue: The six drivers—Repatha, EVENITY, TEZSPIRE, Rare Disease, Innovative Oncology, and Biosimilars—together accounted for more than 70% of product sales, with an overall year-over-year increase of 27%. A total of 17 products achieved double-digit growth this quarter, and another 17 products had annualized sales exceeding $1 billion based on quarterly figures, demonstrating portfolio breadth.

  2. Repatha sales grew 37% YoY to $1.1 billion, with US new prescription weekly growth exceeding 60%: The VESALIUS-CV trial established Repatha as the only PCSK9 inhibitor with Phase 3 cardiovascular outcomes data in both primary and secondary prevention. Updated ACC/AHA guidelines support earlier and more aggressive lowering of LDL-C. Management estimates approximately 100 million patients globally have yet to reach their LDL-C targets, with more than 3 million new patients expected to start Repatha this year.

  3. IMDELLTRA (tarlatamab) sales more than doubled YoY to $406 million, with Phase 3 first-line maintenance data shocking the industry: The DeLLphi-305 study showed that IMDELLTRA combined with IMFINZI in first-line maintenance therapy achieved a median overall survival of 21.1 months, compared to only 12.7 months in the control group—a gain of over 8 months. The FDA has shortened the monitoring time for the first two doses from 22-24 hours to 6-8 hours, significantly lowering the barrier for use in community clinics.

  4. UPLIZNA sales grew 191% YoY to $451 million, with strong QoQ momentum in the Generalized Myasthenia Gravis (gMG) indication: UPLIZNA saw strong demand across all approved indications, with a 45% QoQ increase in new and continuing gMG patients. It has launched in 25 markets outside the US. Long-term follow-up data for IgG4-related disease showed that all patients remaining on treatment stayed relapse-free through the first year of the open-label extension.

  5. Pipeline Harvest: Three Phase 3 clinical trials reported positive results in the same quarter: Phase 3 studies for IMDELLTRA in SCLC first-line maintenance, TEZSPIRE in Eosinophilic Esophagitis (EoE), and dazodalibep in systemic Sjögren's disease all met their primary endpoints. Notably, the CROSSING study for TEZSPIRE was the first placebo-controlled trial to prove that a biologic's efficacy in EoE can be sustained through week 52.

  6. Non-GAAP operating margin reached 47%, exceeding the full-year guidance range: While full-year guidance is approximately 45% to 46%, the actual margin this quarter was 47%; Non-GAAP EPS was $6.45, up approximately 14% from $5.64 in the same period last year; free cash flow was $3.7 billion, supporting continuous R&D and capital expenditure.

  7. Biosimilar portfolio grew 26% YoY to $977 million, PAVBLU grew 41% YoY to $300 million: PAVBLU (EYLEA biosimilar) continues to be adopted by retinal specialists benefiting from the convenience of pre-filled syringes. The next wave of biosimilar candidates for EYLEA HD, OPDIVO, KEYTRUDA, and OCREVUS have all entered late-stage clinical development, representing large market opportunities.

  8. Full-year total revenue guidance raised to $38.9B–$39.7B, Non-GAAP EPS raised to $22.90–$23.70: Both metrics were revised upward from the $38.2B–$39.4B and $22.30–$23.50 ranges provided last quarter, reflecting management's increased confidence in full-year execution.

Sign up for free!

You can sign up for free or Log In to read more information!

Free In-Depth for popular US stocks:

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer